Published in J Thromb Thrombolysis on January 01, 2016
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep (2016) 0.75
Comparison of postoperative complications after total hip arthroplasty among patients receiving aspirin, enoxaparin, warfarin, and factor Xa inhibitors. J Orthop (2017) 0.75
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Heparin. N Engl J Med (1991) 3.66
The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med (1993) 3.43
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Low-molecular-weight heparins. N Engl J Med (1997) 3.19
Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med (1986) 3.00
Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med (2001) 2.89
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65
Treatment of venous thromboembolism. JAMA (2014) 2.63
Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.56
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54
Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos (2008) 2.45
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol (2014) 2.17
Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood (2005) 2.08
Laboratory assessment of new anticoagulants. Clin Chem Lab Med (2011) 1.99
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther (2010) 1.88
Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol (2008) 1.70
The international normalized ratio. A guide to understanding and correcting its problems. Arch Intern Med (1994) 1.66
Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood (2008) 1.64
Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost (1983) 1.62
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther (1974) 1.61
Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost (2009) 1.58
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs (2013) 1.49
Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos (2012) 1.48
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol (2013) 1.39
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost (1995) 1.25
Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother (2009) 1.25
Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. Br J Clin Pharmacol (1994) 1.24
Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med (2007) 1.20
Anticoagulants and their reversal. Transfus Med Rev (2007) 1.18
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost (2013) 1.16
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis (2011) 1.12
The value of plasma calibrants in correcting coagulometer effects on international normalized ratios. An international multicenter study. Am J Clin Pathol (1995) 1.09
Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost (2000) 1.08
Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am (2005) 1.07
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol (2013) 1.05
The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet (2002) 1.01
Prothrombin time and partial thromboplastin time assay considerations. Clin Lab Med (2009) 1.00
The laboratory and the direct oral anticoagulants. Blood (2013) 0.97
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Clin Pharmacokinet (2003) 0.97
Aging and heparin-related bleeding. Arch Intern Med (1996) 0.96
Predictors of bleeding during heparin therapy. JAMA (1980) 0.95
Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost (2011) 0.94
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2013) 0.93
Warfarin-induced changes in procoagulant and anticoagulant proteins. Blood Coagul Fibrinolysis (1995) 0.90
Heparin overview and issues. Pharmacotherapy (2004) 0.90
Update on heparin: what do we need to know? J Thromb Thrombolysis (2010) 0.89
Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol (2015) 0.87
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program (2012) 0.82
Anticoagulant response after dalteparin overdose. J Thromb Haemost (2010) 0.82
New oral therapies for the prevention and treatment of venous thromboembolism. Am J Health Syst Pharm (2013) 0.81
Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis (2013) 0.80
Kinetics of R andS warfarin enantiomers. Clin Pharmacol Ther (1980) 0.79
Genetic regulation of warfarin metabolism and response. Semin Vasc Med (2003) 0.79
Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med (2006) 0.78
Anticoagulation monitoring. Clin Lab Med (2009) 0.78
High-dose intravenous dalteparin can be monitored effectively using standard coagulation times. Clin Appl Thromb Hemost (2005) 0.77
Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy (2004) 0.77
Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors. Ann Pharmacother (2005) 0.77
Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.78